Q&A 2017

Approaching our highly anticipated 4^th Annual Peptides Congress, we sat down with one of our esteemed academic speakers, Timo Müller, Associate Director & Head of Division of Molecular Pharmacology, Helmholtz Center Munich to discuss his research and the peptides industry.

Timo studies Zoology and Animal Physiology at the Phillips-University Marburg, Germany. He received his PhD in 2009 and started to work as a postdoctoral fellow at the Metabolic Disease Institute, University o Cincinnati. In 2001 Timo returned to Germany and since then he is the head of the Division of Molecular Pharmacology. Since 2015 he is also the Associate Director of the Institute for Dibetes and Obesity (IDO), Helmholtz Center Munich.

Click here to read our interview with Timo

Q&A 2016

We sat down with Ronald Jackson, Principal Scientist, MedImmune to talk about the peptides industry and his research.

Ron has been working on peptide related projects since 2007. This included lead discovery projects on analogues of naturally occurring incretin hormones and on intracellular delivery of peptides modulating protein-protein interactions. Ron’s special interest involves display approaches to peptide discovery.

Click here to read our interview with Ronald

For our 2nd Annual Peptides Congress 2015, we spoke with Paul Feldman, Senior Vice President, GlaxoSmithKline and Lyn Jones, Head of Rare Diseases Chemistry, Head of Chemical Biology, Pfizer.

Paul joined Glaxo Pharmaceuticals in 1987 after completing his PhD studies at the University of California, Berkeley. Throughout his career, he has been involved in a variety of drug discovery programs. Paul’s recent achievements include the approval of the HIV integrase inhibitor dolutegravir (Tivicay) in 2013, and the ultra short-acting benzodiazepine, remimazolam entering Phase 2/3 trials in 2012. Paul talked to us about the risks and challenges his group are currently facing.

Click here to read our interview with Paul.

Prior to joining Pfizer, Lyn worked at The Scripps Research Institute, California and was involved in conducting research in the area of chemical biology. His achievements at Pfizer include the delivery of clinical candidates in the areas of HIV, COPD and synthetic vaccines. Lyn will be speaking at the 2nd Annual Peptides Congress in April and has kindly agreed to share his opinion about the ruling trends in the peptides industry.

Click here to read our interview with Lyn.